Now I have enough calibration. Let me write the consolidated review.

**Round-1 bracket**: Between 3.0 and 8.0. Weak anchors at 2.5-3.0 (SBDD method papers), middle at 4.0-5.0 (benchmark papers like Bento, PoseX, PDFBench), strong at 8.0 (not topically similar).

**Round-2 narrowing**: Between 4.0 and 6.0. Key comparators: PepBenchmark (6.0, cleaner methodology), Bento (5.0, comparable scope/rigor), PDFBench (4.0, similar-level methodology issues), FragFM (5.0, method + benchmark).

**Comparison reasoning**: CBGBench is broader than Bento (12 methods × 5 tasks vs 11 tools × 1 task) and more novel in its task formulation, but has more significant methodology concerns (architecture modification, asymmetric training) than either Bento or PepBenchmark. It's clearly above HBDrug3D (3.33) and PDFBench (4.0). I place it at **4.5** — between PDFBench (4.0) and Bento/FragFM (5.0), closer to the 5.0 end.

---

## Summary

CBGBench unifies structure-based drug design (SBDD) tasks (de novo, linker, fragment, side chain, scaffold generation) into a graph completion framework — "fill-in-the-blank of the 3D complex binding graph." It categorizes 12 methods along three dichotomies, implements them in a modular codebase with controlled GNN backbones, extends evaluation to four lead optimization subtasks, and introduces novel metrics (interaction-pattern JSD/MAE from PLIP, ligand binding efficacy, clash ratios). Experimental results across 5 tasks produce a systematic comparison and several empirical insights about method capabilities and limitations.

## Strengths

1. **Unified task formulation enabling systematic extension** — Redefining SBDD as a conditional graph completion task $p(\mathcal{G}|\mathcal{C},\mathcal{P})$ (Section 2.1) provides a clean formalism that naturally extends de novo generation to four lead optimization subtasks. Table 2 concretely shows dataset splits for each task, and Figure 1 visualizes the decomposition. This is a genuine conceptual contribution that no prior benchmark provided.

2. **Substantially broadened evaluation protocol** — The paper goes well beyond standard (QED, SA, Vina) metrics by incorporating interaction-pattern analysis via PLIP (7 interaction types, per-pocket and overall JSD/MAE), ligand binding efficacy (LBE) to control for molecule-size effects in docking scores, and geometry metrics (bond-length/angle JSD, clash ratios). Tables 3-6 demonstrate all 12 methods across four evaluation dimensions (substructure, chemical, interaction, geometry), establishing a more comprehensive standard than any prior single SBDD paper.

3. **Extension to four lead optimization tasks** — While prior SBDD benchmarks focus exclusively on de novo generation, CBGBench adapts the same methods to linker design, fragment growing, side chain decoration, and scaffold hopping (Table 4, Section 5.2). The empirical finding that "scaffold hopping is the most challenging, linker design the easiest" is practically informative, and the observation that most methods produce negative MPBG% (molecules are not improved) honestly identifies the gap between current methods and real optimization needs.

4. **Modular codebase and controlled architecture comparison** — All methods are trained for the same number of iterations (5M) and, within categories, share the same GNN backbone (GVP for autoregressive, EGNN+GAT for diffusion). This enables apples-to-apples comparison of generative procedures rather than conflating method differences with architecture differences — a genuine advance over the scattered, non-reproducible evaluations in the original papers.

## Weaknesses

### Fatal
None.

### Major

1. **Architecture modifications limit the conclusions to controlled variants, not original methods** — The paper replaces the original GNN message-passing architectures of several methods (using GVP for autoregressive models and EGNN+GAT for diffusion models) "to eliminate the effect brought about by the architecture of GNNs" (Section 5.1.1). While this is a defensible choice for a controlled benchmark, it means the paper evaluates *modified versions* of methods. Claims such as "MolCraft achieves the best overall performance" (Section 5.1) or "Pocket2Mol is the state-of-the-art auto-regressive method" technically refer to architecture-controlled variants, not the methods as originally published and used by practitioners. The paper does not quantify the gap between modified and original architectures for any method, so the sensitivity of rankings to this choice is unknown. **Why it matters**: The paper's central claim is providing a "fair comparison" to resolve which methods are best, but the object of comparison has been altered without measuring the impact.

2. **Asymmetric training protocol confounds subtask comparisons** — For the four lead optimization subtasks, autoregressive methods are **fine-tuned** from de novo checkpoints, while diffusion-based one-shot methods are **trained from scratch** (Section 5.2, Setup). The stated justification (zero-center-of-mass shift from protein centers to molecule-context centers) is technically grounded but creates a confound: autoregressive methods benefit from retained molecular representations learned during de novo training, while diffusion methods must learn from fewer examples (43–100 test instances) with random initialization. Consequently, the subtask conclusions — "linker design is the easiest," "scaffold hopping is the most challenging" — cannot be cleanly attributed to method vs. training protocol differences. **Why it matters**: The lead optimization extension is a key contribution, but the protocol asymmetry undermines the interpretability of its primary findings.

### Minor

3. **Overall ranking methodology lacks statistical grounding** — The weighted ranking in Table 5 uses fixed weights (0.2 substructure, 0.2 chemical, 0.4 interaction, 0.2 geometry) with no justification or sensitivity analysis. No confidence intervals, bootstrap estimates, or significance tests are reported for any metric. Given that several metrics are noisy (e.g., docking scores, JSD from small sample sizes of 43–100 test instances), fine-grained rank differences (e.g., ranks 2 vs. 3) may not be meaningful. The ranking formula ("(12−rank)" averaging with tie/missing-value handling) is also underspecified in the main text. Missing values (e.g., methods with no valid Vina Score) are handled opaquely.

4. **Real-world case study claims are stronger than the evidence supports** — The paper states that "the established evaluation protocols exhibit **strong consistency and generalizability on real-world target data**" (Section 5.3). This conclusion is based on t-SNE visualizations of ECFP fingerprints (qualitative overlap) and visual comparison of Vina/LBE distributions — no quantitative metric (e.g., enrichment factor, Tanimoto similarity to known actives) is reported. The t-SNE plots show varying degrees of overlap, and the conclusion is too strong for the evidence presented.

5. **No systematic reporting of molecule validity rates** — The paper mentions that "for some methods like GraphBP, the generated molecules might have troubles in passing the validity check" (Section 5.1.1), but does not report validity rates across all 12 methods. If some methods produce many invalid molecules that are excluded from downstream evaluation, metrics like QED/SA/Vina could be biased toward conservatism.

### Trivial

- Some table formatting issues: line 343 shows "\-5.01" where a minus sign formatting artifact appears.
- The LogP ranking scheme (rank 1 if within [-0.4,5.6], rank 2 otherwise) is explained (Section 5.1.1) but the chemical property tables show numeric LogP values rather than ranks, creating momentary confusion about how LogP enters the overall ranking.

## Nice-to-Haves

- **Diversity metric**: The paper evaluates substructure distributions (atom/ring/functional group JSD and MAE) which capture population-level diversity of chemical features, but a per-molecule diversity metric (e.g., average pairwise Tanimoto distance between generated molecules for each pocket) would strengthen analysis of method practicality.
- **Architecture sensitivity analysis**: Running at least one autoregressive and one diffusion method with both original and modified architecture on a subset of metrics would quantify the impact of the controlled-architecture choice and bound the robustness of conclusions.
- **Harmonized subtask training**: Training all methods from scratch for subtasks (or finding a protocol that treats all methods symmetrically) would eliminate the current confound, though the computational cost is acknowledged.
- **LogP ranking clarity**: Showing both the raw LogP value and a column indicating the rank (1 or 2) in the overall ranking table would remove confusion.

## Removed Points

*These points are flagged to be removed; treat them with caution.*

- **"Taxonomy not orthogonal"** (Harsh Critic, Section 2 notes): The taxonomy makes no claim of orthogonality; it presents three descriptive dichotomies. Not a weakness.
- **"LiGAN is CNN-based but uses VAE, not diffusion"**: The term "CNN-based" refers to the architecture family (CNN for voxel processing), not the generative approach (VAE vs diffusion). The paper's discussion of LiGAN clearly states it uses a VAE. No confusion in the actual text.
- **"LogP ranking is confusing"** / **"tables show numeric LogP values"**: The paper separately shows raw metric values and explains the ranking scheme. This is standard practice — show the metric, derive the rank. The scheme is transparent.
- **"Codebase not described in enough detail"**: Appendix is stripped by the parser. The paper states the appendix contains implementation details. Parser artifact.
- **"Performance gap not pronounced is unsupported"**: This is a textual observation from the tables, not a statistical claim. Reasonable qualitative analysis.

## Novel Insights

None beyond the paper's own contributions. The reviews surface known trade-offs in benchmark design (controlled architecture vs. fidelity to original methods, training protocol consistency vs. technical constraints) that the paper acknowledges but does not fully resolve. The most useful observation from the reviews is the aggregation of these concerns: the paper would benefit from making the controlled-architecture choice an explicit *sensitivity analysis* rather than a fixed design decision, and from quantifying the asymmetry in subtask training rather than treating it as a footnote.

## Suggestions

1. **Quantify the architecture gap**: For at least one autoregressive method (e.g., Pocket2Mol) and one diffusion method (e.g., TargetDiff), compare the original architecture version with the controlled-architecture version on a subset of de novo metrics. Report whether rankings shift. This would either validate the fairness claim or bound its impact — either outcome is informative.
2. **Acknowledge the subtask training asymmetry as a limitation**: Add an explicit statement in Section 5.2 that the fine-tune-from-scratch asymmetry confounds method comparisons, and resist drawing strong method-level conclusions from the subtask results without caveats.
3. **Add confidence intervals**: Report standard deviations across multiple seeds or bootstrapped confidence intervals for key metrics (Vina, JSD values) so readers can assess whether rank differences are meaningful.
4. **Add a diversity metric**: Average pairwise Tanimoto distance between generated molecules for each pocket is cheap to compute and provides useful signal about mode collapse.
5. **Report per-method validity rates**: A single column showing the % of valid molecules (RDKit-sanitizable) after generation would add important context to all other metrics.

## Score and Decision

**Calibration anchors retrieved:**

| Anchor | Path | Avg Score | Round | Comparison |
|--------|------|-----------|-------|------------|
| PFM SBDD | CEuzrRs613.md | 2.67 | R1 (low) | Method paper, not benchmark. CBGBench much stronger in scope and utility. |
| DockedAC | fgooGoezZJ.md | 3.00 | R1 (low) | Dataset paper, narrower scope. CBGBench stronger. |
| PharmaDiff | o8kZQdLROK.md | 2.50 | R1 (low) | Method paper with conceptual concerns. CBGBench stronger. |
| RL4SBDD | dWEQpTkr1v.md | 4.50 | R2 (mid) | Method paper, criticized for diversity issues. CBGBench comparable overall quality. |
| Bento | kIxAQxUZHq.md | 5.00 | R2 (mid) | Docking benchmark, cleaner methodology but narrower scope. CBGBench comparable. |
| PoseX | qqzxKudD4T.md | 5.00 | R2 (mid) | Docking benchmark, incrementality concerns. CBGBench somewhat stronger in novelty. |
| PepBenchmark | NskQgtSdll.md | 6.00 | R2 (high-mid) | Cleaner methodology, narrower scope (peptide property prediction). CBGBench weaker in rigor. |
| PDFBench | 4blGqgStVr.md | 4.00 | R2 (mid) | Similar methodology concerns. CBGBench stronger in empirical depth. |
| HBDrug3D | HAZuDos7c7.md | 3.33 | R2 (mid) | Narrower scope (linkers only), only 2 working baselines. CBGBench clearly stronger. |
| FragFM | tr6vRn2aPg.md | 5.00 | R2 (mid) | Method + benchmark. CBGBench comparable as a benchmark contribution. |
| MolLangBench | KbXl2jfFRn.md | 5.00 | R2 (mid) | Language-molecule benchmark, different domain. Comparable quality tier. |
| S2-Bench | qTTmUJFG38.md | 4.67 | R2 (mid) | LLM molecule benchmark, different domain. Comparable tier. |

**Bracket**: R1 placed paper between 3.0 and 8.0. R2 narrowed to 4.0-6.0 by comparison with PDFBench (4.0), Bento (5.0), PepBenchmark (6.0), and others.

**Final position**: The paper has genuine contributions (unified task formulation, broadened evaluation, 4 subtask extensions, modular codebase) that place it clearly above PDFBench (4.0) and the sub-4.0 papers. However, two methodological concerns — architecture modifications altering the object of comparison and asymmetric training protocols in subtasks — prevent it from reaching the clean-rigor tier of PepBenchmark (6.0). It is comparable to Bento (5.0) and PoseX (5.0) in overall utility, just on different dimensions (broader scope but messier methodology). Placing it at **4.5** reflects a solid benchmark contribution with important caveats.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>